Pier 88 Investment Partners LLC Sells 23,020 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Pier 88 Investment Partners LLC reduced its stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 18.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 98,590 shares of the company’s stock after selling 23,020 shares during the period. Pier 88 Investment Partners LLC owned 0.17% of Pyxis Oncology worth $154,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Intech Investment Management LLC bought a new stake in Pyxis Oncology in the 3rd quarter valued at about $55,000. MetLife Investment Management LLC increased its holdings in shares of Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after acquiring an additional 5,484 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of Pyxis Oncology by 61.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after purchasing an additional 10,000 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Pyxis Oncology during the third quarter worth approximately $107,000. Finally, Jane Street Group LLC lifted its holdings in shares of Pyxis Oncology by 40.8% in the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after purchasing an additional 14,349 shares in the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.06 on Monday. The company has a fifty day moving average price of $1.29 and a 200-day moving average price of $2.26. Pyxis Oncology, Inc. has a 1 year low of $0.99 and a 1 year high of $6.18. The firm has a market cap of $65.29 million, a price-to-earnings ratio of -1.03 and a beta of 1.11.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.01. The firm had revenue of $16.15 million during the quarter. On average, research analysts anticipate that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on PYXS shares. Royal Bank of Canada restated an “outperform” rating and set a $8.00 price objective on shares of Pyxis Oncology in a report on Wednesday, March 19th. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Pyxis Oncology in a report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.20.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.